Last Updated : April 22, 2022
This Horizon Scan summarizes the available information regarding the emerging technology of liquid biopsy–based multi-cancer early detection tests for cancer screening. This scan focuses specifically on the Galleri (GRAIL Inc.) and CancerSEEK (Exact Sciences) tests, which are further along in the development cycle and are being assessed in different international clinical studies. The scan also highlights some issues for health care decision-makers to consider about the technology relating to real-world test performance, the potential benefits and harms of screening with multi-cancer early detection tests, and the disruptiveness to health systems these tests could pose. Ongoing review of clinical trials and the emerging evidence base can help inform health systems in Canada about their potential role within cancer-control initiatives.